➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
Boehringer Ingelheim
McKinsey
Colorcon

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Par Sterile Products Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for PAR STERILE PRODUCTS, and when can generic versions of PAR STERILE PRODUCTS drugs launch?

PAR STERILE PRODUCTS has thirty-two approved drugs.

There are seventeen US patents protecting PAR STERILE PRODUCTS drugs. There is one tentative approval on PAR STERILE PRODUCTS drugs.

There are seven patent family members on PAR STERILE PRODUCTS drugs in seven countries and fifty supplementary protection certificates in fourteen countries.

Summary for Par Sterile Products
International Patents:7
US Patents:17
Tradenames:29
Ingredients:29
NDAs:32
Patent Litigation for Par Sterile Products: See patent lawsuits for Par Sterile Products

Drugs and US Patents for Par Sterile Products

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Sterile Products PITOCIN oxytocin INJECTABLE;INJECTION 018261-002 Jul 27, 2007 AP RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Par Sterile Products ETHACRYNATE SODIUM ethacrynate sodium INJECTABLE;INJECTION 205473-001 Jul 29, 2015 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Par Sterile Products VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-004 Apr 15, 2020 RX Yes Yes 9,981,006 ⤷  Free Forever Trial ⤷  Free Forever Trial
Par Sterile Products TREPROSTINIL treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 209382-003 Sep 24, 2019 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Par Sterile Products VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-004 Apr 15, 2020 RX Yes Yes 9,925,234 ⤷  Free Forever Trial ⤷  Free Forever Trial
Par Sterile Products VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-003 Apr 15, 2020 RX Yes Yes 10,010,575 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Par Sterile Products

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Sterile Products DANTRIUM dantrolene sodium CAPSULE;ORAL 017443-001 Approved Prior to Jan 1, 1982 3,415,821 ⤷  Free Forever Trial
Par Sterile Products DANTRIUM dantrolene sodium CAPSULE;ORAL 017443-002 Approved Prior to Jan 1, 1982 3,415,821 ⤷  Free Forever Trial
Par Sterile Products DANTRIUM dantrolene sodium CAPSULE;ORAL 017443-003 Approved Prior to Jan 1, 1982 3,415,821 ⤷  Free Forever Trial
Par Sterile Products DANTRIUM dantrolene sodium INJECTABLE;INJECTION 018264-001 Approved Prior to Jan 1, 1982 3,415,821 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PAR STERILE PRODUCTS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 20 units/mL, 1 mL ➤ Subscribe 2018-03-23
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Injection 1 mg/mL ampules ➤ Subscribe 2016-03-09
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01

International Patents for Par Sterile Products Drugs

Country Patent Number Estimated Expiration
Canada 2978464 ⤷  Free Forever Trial
Japan 2018507915 ⤷  Free Forever Trial
China 107614017 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2016149028 ⤷  Free Forever Trial
Australia 2016233682 ⤷  Free Forever Trial
European Patent Office 3268045 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Par Sterile Products Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0694547 03C0003 France ⤷  Free Forever Trial PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
1380301 CA 2009 00017 Denmark ⤷  Free Forever Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1534313 92923 Luxembourg ⤷  Free Forever Trial PRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
0770388 09C0018 France ⤷  Free Forever Trial PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
0694547 C300071 Netherlands ⤷  Free Forever Trial PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
0770388 PA2009004,C0770388 Lithuania ⤷  Free Forever Trial PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Baxter
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.